Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
432 GBX | -0.80% | +1.05% | +3.35% |
May. 07 | AstraZeneca target raised; Antofagasta lowered | AN |
Apr. 25 | SThree plc Approves Final Dividend | CI |
Sales 2024 * | 1.65B 2.1B | Sales 2025 * | 1.76B 2.23B | Capitalization | 574M 729M |
---|---|---|---|---|---|
Net income 2024 * | 51M 64.77M | Net income 2025 * | 60M 76.2M | EV / Sales 2024 * | 0.3 x |
Net cash position 2024 * | 71.54M 90.85M | Net cash position 2025 * | 78.93M 100M | EV / Sales 2025 * | 0.28 x |
P/E ratio 2024 * |
11.3
x | P/E ratio 2025 * |
9.66
x | Employees | 2,654 |
Yield 2024 * |
3.73% | Yield 2025 * |
4.07% | Free-Float | 88.78% |
Latest transcript on SThree plc
1 day | -0.80% | ||
1 week | +1.05% | ||
Current month | +1.29% | ||
1 month | +1.65% | ||
3 months | +0.93% | ||
6 months | +7.60% | ||
Current year | +3.35% |
Managers | Title | Age | Since |
---|---|---|---|
Timo Lehne
CEO | Chief Executive Officer | - | 21-12-31 |
Andrew Beach
DFI | Director of Finance/CFO | 49 | 21-07-04 |
Nick Folkes
COO | Chief Operating Officer | - | 20-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Elaine O'Donnell
BRD | Director/Board Member | 53 | 22-09-30 |
Director/Board Member | - | 22-11-30 | |
James Bilefield
CHM | Chairman | 55 | 17-09-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 10 M€ | -3.35% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 432 | -0.80% | 89,123 |
24-05-16 | 435.5 | +0.35% | 285,894 |
24-05-15 | 434 | +0.35% | 50,112 |
24-05-14 | 432.5 | -0.23% | 93,301 |
24-05-13 | 433.5 | +1.40% | 164,303 |
Delayed Quote London S.E., May 17, 2024 at 11:35 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+3.35% | 730M | |
-10.54% | 9.78B | |
-19.39% | 7.31B | |
-12.38% | 6.68B | |
-3.28% | 3.67B | |
-1.32% | 3.51B | |
+12.17% | 1.65B | |
+0.21% | 1.52B | |
+11.14% | 1.51B | |
-5.17% | 1.2B |
- Stock Market
- Equities
- STHR Stock